SCHEMBL6523246

SCHEMBL6523246

CCN(CC)CCCN.O=C1Cc2cc(Br)ccc2N1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AHR P35869 2/20 0.47
CMA1 P23946 1/20 0.47
SMYD3 Q9H7B4 6/20 0.45
MAOA P21397 4/20 0.42
MAOB P27338 4/20 0.42
TDP2 O95551 1/20 0.42
GRIA1 P42261 2/20 0.40
CACNG8 Q8WXS5 2/20 0.40
BRD4 O60885 1/20 0.40
IDO1 P14902 1/20 0.40
GAA P10253 1/20 0.38
PDE3B Q13370 1/20 0.37
PDE3A Q14432 1/20 0.37
CCNB2 O95067 1/20 0.36
CDK1 P06493 1/20 0.36
CCNB1 P14635 1/20 0.36
GSK3B P49841 1/20 0.36
CCNB3 Q8WWL7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6431 0.78 AHR (0.72) AHRCMA1TDP2GRIA1CACNG8
SCHEMBL6424642 0.74 SMYD3 (0.48) SMYD3GAA
SCHEMBL6525674 0.74 AHR (0.45) AHRCMA1SMYD3TDP2GRIA1
Formic Acid SCHEMBL29737119 0.71 AHR (0.62) AHRCMA1SMYD3TDP2GRIA1
SCHEMBL6424640 0.70 SIGMAR1 (0.53) SMYD3IDO1
SCHEMBL7715803 0.68 PGR (0.62) AHRCMA1TDP2GRIA1CACNG8
Methylamine SCHEMBL27858404 0.68 AHR (0.89) AHRCMA1SMYD3TDP2GRIA1
Tert-Butyl Formate SCHEMBL27780535 0.68 AHR (0.53) AHRCMA1MAOBTDP2GRIA1
SCHEMBL6360379 0.68 SMYD3 (0.64) SMYD3
SCHEMBL9096698 0.67 AHR (0.51) AHRMAOBGRIA1CACNG8GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1427326-A4 COMBINATION THERAPY FOR THE TREATMENT OF CANCER SUGEN INC (US) 2005-06-08 EP disclosed
EP-1427326-A2 COMBINATION THERAPY FOR THE TREATMENT OF CANCER Sugen, Inc. (US) 2004-06-16 EP disclosed
WO-2003015608-A2 COMBINATION THERAPY FOR THE TREATMENT OF CANCER SUGEN, INC. (US) 2003-02-27 WO disclosed